Long Term Outcomes of Lung Transplantation in Sensitized Patients Following Eculizumab Use With the Desensitization Protocol
Transplant International · 2025
DOI: 10.3389/ti.2025.15040 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Transplant International, 2025. Verfasst von Yudai Miyashita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. Hauptthemen laut MEDLINE: Lung Transplantation, Antibodies, Monoclonal, Humanized, Desensitization, Immunologic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung transplantation remains a life-saving option for end-stage pulmonary diseases, but sensitized patients with anti HLA antibodies carry high risk; recent desensitization advances, such as eculizumab, may permit outcomes comparable to non-sensitized recipients with tailored perioperative care. In this prospective cohort study of 399 adult lung transplant recipients, 36 sensitized patients underwent a protocol combining preoperative plasmapheresis, a defined eculizumab regimen, anti-thymocyte globulin, and IVIG. In comparison, 363 non-sensitized recipients received standard immunosuppression. We compared recipient/donor characteristics, intraoperative parameters, and postoperative outcomes, including primary graft dysfunction, infection, rejection, and overall survival. Desensitized patients were older, predominantly female, and had significantly higher panel reactive antibody levels and preformed donor-specific antibodies; intraoperatively, they required more blood transfusions and VA-ECMO support. Postoperatively, they exhibited higher rates of de novo donor-specific antibodies, antibody-mediated rejection, longer ICU stays, increased dialysis requirement, and more frequent CMV infections. Despite these differences, rates of acute cellular rejection, chronic lung allograft dysfunction, and one-year and overall survival were similar between groups. Our findings suggest that lung transplantation in sensitized patients managed with a desensitization protocol, including eculizumab, is feasible and safe, achieving outcomes comparable to those of non-sensitized recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
- Division of Transplant, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Zitieren
APA
Miyashita, Y., Kaiho, T., Pinelli, D. F., Joudi, A., John, M., Chang, A., Thomae, B. L., Kamar, A., Atkinson, C., Bharat, A., Budinger, G. R. S., Arunachalam, A., & Kurihara, C. (2025). Long Term Outcomes of Lung Transplantation in Sensitized Patients Following Eculizumab Use With the Desensitization Protocol. Transplant International. https://doi.org/10.3389/ti.2025.15040
Vancouver
Miyashita Y, Kaiho T, Pinelli DF, Joudi A, John M, Chang A, et al. Long Term Outcomes of Lung Transplantation in Sensitized Patients Following Eculizumab Use With the Desensitization Protocol. Transplant International. 2025. doi:10.3389/ti.2025.15040
BibTeX
@article{Miyashita2025,
author = {Miyashita, Yudai and Kaiho, Taisuke and Pinelli, David F and Joudi, Anthony and John, Mihir and Chang, Austin and Thomae, Benjamin Louis and Kamar, Amanda and Atkinson, Carl and Bharat, Ankit and Budinger, G R Scott and Arunachalam, Ambalavanan and Kurihara, Chitaru},
title = {Long Term Outcomes of Lung Transplantation in Sensitized Patients Following Eculizumab Use With the Desensitization Protocol},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2025.15040}
}
EUVIMED